Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease

FEBS Letters

Volumn 589, Issue 24, 2015, Pages 3702-3713

  Haddad, Dominik ^a   Nakamura, Ken ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioenergetics; Dopamine; Mitochondria; Neurodegeneration; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PARKIN; VESICULAR MONOAMINE TRANSPORTER 2; CALCIUM;

AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE MUTATION; HUMAN; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRESS; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; ENERGY METABOLISM; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS;

ANIMALS; CALCIUM; DOPAMINERGIC NEURONS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; PARKINSON DISEASE; STRESS, PHYSIOLOGICAL;

EID: 84948687112     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.10.021     Document Type: Review

References (229)

1. E. Lezi, and R.H. Swerdlow Mitochondria in neurodegeneration Adv. Exp. Med. Biol. 942 2012 269 286
2. D. Mahad, H. Lassmann, and D. Turnbull Review: mitochondria and disease progression in multiple sclerosis Neuropathol. Appl. Neurobiol. 34 2008 577 589
3. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
4. S. Przedborski, V. Jackson-Lewis, A.B. Naini, M. Jakowec, G. Petzinger, R. Miller, and M. Akram The Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety J. Neurochem. 76 2001 1265 1274
5. C.L. Hoppel, D. Grinblatt, H.C. Kwok, P.K. Arora, M.P. Singh, and L.M. Sayre Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP Biochem. Biophys. Res. Commun. 148 1987 684 693
6. R.R. Ramsay, J.I. Salach, J. Dadgar, and T.P. Singer Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism Biochem. Biophys. Res. Commun. 135 1986 269 275
7. K. Miyako, Y. Kai, T. Irie, K. Takeshige, and D. Kang The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridinium ion (MPP+) J. Biol. Chem. 272 1997 9605 9608
8. F. Soldner, M. Weller, S. Haid, S. Beinroth, S.W. Miller, U. Wullner, R.E. Davis, J. Dichgans, T. Klockgether, and J.B. Schulz MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1) Exp. Cell Res. 250 1999 75 85
9. K. Nakamura, V.P. Bindokas, J.D. Marks, D.A. Wright, D.M. Frim, R.J. Miller, and U.J. Kang The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited Mol. Pharmacol. 58 2000 271 278
10. J. Wang, Z. Xu, H. Fang, H.M. Duhart, T.A. Patterson, and S.F. Ali Gene expression profiling of MPP+-treated MN9D cells: a mechanism of toxicity study Neurotoxicology 28 2007 979 987
11. W.S. Choi, S.E. Kruse, R.D. Palmiter, and Z. Xia Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat Proc. Natl. Acad. Sci. U.S.A. 105 2008 15136 15141
12. Y. Mizuno, T. Saitoh, and N. Sone Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion Biochem. Biophys. Res. Commun. 143 1987 971 976
13. J.A. Javitch, R.J. D'Amato, S.M. Strittmatter, and S.H. Snyder Parkinsonism-induced neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proc. Natl. Acad. Sci. U.S.A. 82 1985 2173 2177
14. C. Pifl, B. Giros, and M.G. Caron Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium J. Neurosci. 13 1993 4246 4253
15. Y. Liu, D. Peter, A. Roghani, S. Schuldiner, G.G. Prive, D. Eisenberg, N. Brecha, and R.H. Edwards A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70 1992 539 551
16. Y. Liu, A. Roghani, and R.H. Edwards Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium Proc. Natl. Acad. Sci. U.S.A. 89 1992 9074 9078
17. J.R. Tormo, T. Gallardo, E. Peris, A. Bermejo, N. Cabedo, E. Estornell, M.C. Zafra-Polo, and D. Cortes Inhibitory effects on mitochondrial complex I of semisynthetic mono-tetrahydrofuran acetogenin derivatives Bioorg. Med. Chem. Lett. 13 2003 4101 4105
18. S. Giordano, J. Lee, V.M. Darley-Usmar, and J. Zhang Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death PLoS One 7 2012 e44610
19. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
20. J.R. Cannon, V. Tapias, H.M. Na, A.S. Honick, R.E. Drolet, and J.T. Greenamyre A highly reproducible rotenone model of Parkinson's disease Neurobiol. Dis. 34 2009 279 290
21. C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, M. Korell, C. Marras, G.S. Bhudhikanok, M. Kasten, A.R. Chade, K. Comyns, M.B. Richards, C. Meng, B. Priestley, H.H. Fernandez, F. Cambi, D.M. Umbach, A. Blair, D.P. Sandler, and J.W. Langston Rotenone, paraquat, and Parkinson's disease Environ. Health Perspect. 119 2011 866 872
22. L. Massieu, P. Del Rio, and T. Montiel Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates Neuroscience 106 2001 669 677
23. E. Brouillet, C. Jacquard, N. Bizat, and D. Blum 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease J. Neurochem. 95 2005 1521 1540
24. J.G. Greene, and J.T. Greenamyre Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate J. Neurochem. 64 1995 430 436
25. W.S. Choi, R.D. Palmiter, and Z. Xia Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model J. Cell Biol. 192 2011 873 882
26. F.H. Sterky, A.F. Hoffman, D. Milenkovic, B. Bao, A. Paganelli, D. Edgar, R. Wibom, C.R. Lupica, L. Olson, and N.G. Larsson Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons Hum. Mol. Genet. 21 2012 1078 1089
27. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, S. Gispert, Z. Ali, D. Del Turco, A.R. Bentivoglio, D.G. Healy, A. Albanese, R. Nussbaum, R. Gonzalez-Maldonado, T. Deller, S. Salvi, P. Cortelli, W.P. Gilks, D.S. Latchman, R.J. Harvey, B. Dallapiccola, G. Auburger, and N.W. Wood Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
28. L. Ricciardi, S. Petrucci, A. Guidubaldi, T. Ialongo, L. Serra, A. Ferraris, B. Spano, M. Bozzali, E.M. Valente, and A.R. Bentivoglio Phenotypic variability of PINK1 expression: 12 years' clinical follow-up of two Italian families Mov. Disord. 29 2014 1561 1566
29. D.P. Narendra, S.M. Jin, A. Tanaka, D.F. Suen, C.A. Gautier, J. Shen, M.R. Cookson, and R.J. Youle PINK1 is selectively stabilized on impaired mitochondria to activate Parkin PLoS Biol. 8 2010 e1000298
30. V.A. Morais, D. Haddad, K. Craessaerts, P.J. De Bock, J. Swerts, S. Vilain, L. Aerts, L. Overbergh, A. Grunewald, P. Seibler, C. Klein, K. Gevaert, P. Verstreken, and B. De Strooper PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling Science 344 2014 203 207
31. K. Itoh, K. Nakamura, M. Iijima, and H. Sesaki Mitochondrial dynamics in neurodegeneration Trends Cell Biol. 23 2013 64 71
32. X. Wang, D. Winter, G. Ashrafi, J. Schlehe, Y.L. Wong, D. Selkoe, S. Rice, J. Steen, M.J. LaVoie, and T.L. Schwarz PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility Cell 147 2011 893 906
33. W. Lin, N.L. Wadlington, L. Chen, X. Zhuang, J.R. Brorson, and U.J. Kang Loss of PINK1 attenuates HIF-1alpha induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia J. Neurosci. 34 2014 3079 3089
34. M.E. Haque, K.J. Thomas, C. D'Souza, S. Callaghan, T. Kitada, R.S. Slack, P. Fraser, M.R. Cookson, A. Tandon, and D.S. Park Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP Proc. Natl. Acad. Sci. U.S.A. 105 2008 1716 1721
35. A. Beilina, M. Van Der Brug, R. Ahmad, S. Kesavapany, D.W. Miller, G.A. Petsko, and M.R. Cookson Mutations in PTEN-induced putative kinase 1 associated with recessive Parkinsonism have differential effects on protein stability Proc. Natl. Acad. Sci. U.S.A. 102 2005 5703 5708
36. A. Weihofen, B. Ostaszewski, Y. Minami, and D.J. Selkoe Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1 Hum. Mol. Genet. 17 2008 602 616
37. W. Lin, and U.J. Kang Characterization of PINK1 processing, stability, and subcellular localization J. Neurochem. 106 2008 464 474
38. D. Narendra, A. Tanaka, D.F. Suen, and R.J. Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J. Cell Biol. 183 2008 795 803
39. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, J.H. Seol, S.J. Yoo, B.A. Hay, and M. Guo Drosophila pink1 is required for mitochondrial function and interacts genetically with Parkin Nature 441 2006 1162 1166
40. J. Park, S.B. Lee, S. Lee, Y. Kim, S. Song, S. Kim, E. Bae, J. Kim, M. Shong, J.M. Kim, and J. Chung Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin Nature 441 2006 1157 1161
41. J.H. Shin, H.S. Ko, H. Kang, Y. Lee, Y.I. Lee, O. Pletinkova, J.C. Troconso, V.L. Dawson, and T.M. Dawson PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease Cell 144 2011 689 702
42. L.Y. Hao, B.I. Giasson, and N.M. Bonini DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function Proc. Natl. Acad. Sci. U.S.A. 107 2010 9747 9752
43. J.N. Guzman, J. Sanchez-Padilla, D. Wokosin, J. Kondapalli, E. Ilijic, P.T. Schumacker, and D.J. Surmeier Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 468 2010 696 700
44. X. Wang, T.G. Petrie, Y. Liu, J. Liu, H. Fujioka, and X. Zhu Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction J. Neurochem. 121 2012 830 839
45. E. Andres-Mateos, C. Perier, L. Zhang, B. Blanchard-Fillion, T.M. Greco, B. Thomas, H.S. Ko, M. Sasaki, H. Ischiropoulos, S. Przedborski, T.M. Dawson, and V.L. Dawson DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase Proc. Natl. Acad. Sci. U.S.A. 104 2007 14807 14812
46. I. Irrcher, H. Aleyasin, E.L. Seifert, S.J. Hewitt, S. Chhabra, M. Phillips, A.K. Lutz, M.W. Rousseaux, L. Bevilacqua, A. Jahani-Asl, S. Callaghan, J.G. MacLaurin, K.F. Winklhofer, P. Rizzu, P. Rippstein, R.H. Kim, C.X. Chen, E.A. Fon, R.S. Slack, M.E. Harper, H.M. McBride, T.W. Mak, and D.S. Park Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics Hum. Mol. Genet. 19 2010 3734 3746
47. F. Kamp, N. Exner, A.K. Lutz, N. Wender, J. Hegermann, B. Brunner, B. Nuscher, T. Bartels, A. Giese, K. Beyer, S. Eimer, K.F. Winklhofer, and C. Haass Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1 EMBO J. 29 2010 3571 3589
48. L. Fallon, C.M. Belanger, A.T. Corera, M. Kontogiannea, E. Regan-Klapisz, F. Moreau, J. Voortman, M. Haber, G. Rouleau, T. Thorarinsdottir, A. Brice, P.M. van Bergen En Henegouwen, and E.A. Fon A regulated interaction with the UIM protein Eps15 implicates Parkin in EGF receptor trafficking and PI(3)K-Akt signalling Nat. Cell Biol. 8 2006 834 842
49. Q. Jiang, Y. Ren, and J. Feng Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome J. Neurosci. 28 2008 12993 13002
50. C.A. da Costa, C. Sunyach, E. Giaime, A. West, O. Corti, A. Brice, S. Safe, P.M. Abou-Sleiman, N.W. Wood, H. Takahashi, M.S. Goldberg, J. Shen, and F. Checler Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease Nat. Cell Biol. 11 2009 1370 1375
51. R. von Coelln, V.L. Dawson, and T.M. Dawson Parkin-associated Parkinson's disease Cell Tissue Res. 318 2004 175 184
52. H. Ariga, K. Takahashi-Niki, I. Kato, H. Maita, T. Niki, and S.M. Iguchi-Ariga Neuroprotective function of DJ-1 in Parkinson's disease Oxid. Med. Cell Longev. 2013 2013 683920
53. M. Funayama, K. Ohe, T. Amo, N. Furuya, J. Yamaguchi, S. Saiki, Y. Li, K. Ogaki, M. Ando, H. Yoshino, H. Tomiyama, K. Nishioka, K. Hasegawa, H. Saiki, W. Satake, K. Mogushi, R. Sasaki, Y. Kokubo, S. Kuzuhara, T. Toda, Y. Mizuno, Y. Uchiyama, K. Ohno, and N. Hattori CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study Lancet Neurol. 14 2015 274 282
54. S. Aras, M. Bai, I. Lee, R. Springett, M. Huttemann, and L.I. Grossman MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism Mitochondrion 20 2015 43 51
55. J.M. Baughman, R. Nilsson, V.M. Gohil, D.H. Arlow, Z. Gauhar, and V.K. Mootha A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis PLoS Genet. 5 2009 e1000590
56. K. Nakamura, V.M. Nemani, F. Azarbal, G. Skibinski, J.M. Levy, K. Egami, L. Munishkina, J. Zhang, B. Gardner, J. Wakabayashi, H. Sesaki, Y. Cheng, S. Finkbeiner, R.L. Nussbaum, E. Masliah, and R.H. Edwards Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein J. Biol. Chem. 286 2011 20710 20726
57. L. Devi, V. Raghavendran, B.M. Prabhu, N.G. Avadhani, and H.K. Anandatheerthavarada Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J. Biol. Chem. 283 2008 9089 9100
58. V. Loeb, E. Yakunin, A. Saada, and R. Sharon The transgenic over expression of alpha-synuclein and not its related pathology, associates with complex I inhibition J. Biol. Chem. 285 2010 7334 7343
59. K. Nakamura Alpha-synuclein and mitochondria: partners in crime? Neurotherapeutics 10 2013 391 399
60. J.T. Bendor, T.P. Logan, and R.H. Edwards The function of alpha-synuclein Neuron 79 2013 1044 1066
61. S. Saha, M.D. Guillily, A. Ferree, J. Lanceta, D. Chan, J. Ghosh, C.H. Hsu, L. Segal, K. Raghavan, K. Matsumoto, N. Hisamoto, T. Kuwahara, T. Iwatsubo, L. Moore, L. Goldstein, M. Cookson, and B. Wolozin LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans J. Neurosci. 29 2009 9210 9218
62. O. Cooper, H. Seo, S. Andrabi, C. Guardia-Laguarta, J. Graziotto, M. Sundberg, J.R. McLean, L. Carrillo-Reid, Z. Xie, T. Osborn, G. Hargus, M. Deleidi, T. Lawson, H. Bogetofte, E. Perez-Torres, L. Clark, C. Moskowitz, J. Mazzulli, L. Chen, L. Volpicelli-Daley, N. Romero, H. Jiang, R.J. Uitti, Z. Huang, G. Opala, L.A. Scarffe, V.L. Dawson, C. Klein, J. Feng, O.A. Ross, J.Q. Trojanowski, V.M. Lee, K. Marder, D.J. Surmeier, Z.K. Wszolek, S. Przedborski, D. Krainc, T.M. Dawson, and O. Isacson Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease Sci. Transl. Med. 4 2012 141ra90
63. S.J. Cherra 3rd, E. Steer, A.M. Gusdon, K. Kiselyov, and C.T. Chu Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons Am. J. Pathol. 182 2013 474 484
64. X. Wang, M.H. Yan, H. Fujioka, J. Liu, A. Wilson-Delfosse, S.G. Chen, G. Perry, G. Casadesus, and X. Zhu LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1 Hum. Mol. Genet. 21 2012 1931 1944
65. L.H. Sanders, J. Laganiere, O. Cooper, S.K. Mak, B.J. Vu, Y.A. Huang, D.E. Paschon, M. Vangipuram, R. Sundararajan, F.D. Urnov, J.W. Langston, P.D. Gregory, H.S. Zhang, J.T. Greenamyre, O. Isacson, and B. Schule LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction Neurobiol. Dis. 62 2014 381 386
66. J.E. Ahlskog Parkin and PINK1 Parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease Parkinsonism Relat. Disord. 15 2009 721 727
67. K. Nishioka, M. Kefi, B. Jasinska-Myga, C. Wider, C. Vilarino-Guell, O.A. Ross, M.G. Heckman, L.T. Middleton, L. Ishihara-Paul, R.A. Gibson, R. Amouri, S. Ben Yahmed, S. Ben Sassi, M. Zouari, G. El Euch, M.J. Farrer, and F. Hentati A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease J. Neurol. Neurosurg. Psychiatry 81 2010 391 395
68. C. Klein, P.P. Pramstaller, B. Kis, C.C. Page, M. Kann, J. Leung, H. Woodward, C.C. Castellan, M. Scherer, P. Vieregge, X.O. Breakefield, P.L. Kramer, and L.J. Ozelius Parkin deletions in a family with adult-onset, tremor-dominant Parkinsonism: expanding the phenotype Ann. Neurol. 48 2000 65 71
69. R.N. Alcalay, E. Caccappolo, H. Mejia-Santana, M.X. Tang, L. Rosado, B.M. Ross, M. Verbitsky, S. Kisselev, E.D. Louis, C. Comella, A. Colcher, D. Jennings, M.A. Nance, S.B. Bressman, W.K. Scott, C. Tanner, S. Mickel, H. Andrews, C. Waters, S. Fahn, L. Cote, S. Frucht, B. Ford, M. Rezak, K. Novak, J.H. Friedman, R. Pfeiffer, L. Marsh, B. Hiner, A. Siderowf, R. Ottman, K. Marder, and L.N. Clark Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study Arch. Neurol. 67 2010 1116 1122
70. M.G. Macedo, D. Verbaan, Y. Fang, S.M. van Rooden, M. Visser, B. Anar, A. Uras, J.L. Groen, P. Rizzu, J.J. van Hilten, and P. Heutink Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease Mov. Disord. 24 2009 196 203
71. R.N. Alcalay, E. Caccappolo, H. Mejia-Santana, M.X. Tang, L. Rosado, M. Orbe Reilly, D. Ruiz, E.D. Louis, C.L. Comella, M.A. Nance, S.B. Bressman, W.K. Scott, C.M. Tanner, S.F. Mickel, C.H. Waters, S. Fahn, L.J. Cote, S.J. Frucht, B. Ford, M. Rezak, K.E. Novak, J.H. Friedman, R.F. Pfeiffer, L. Marsh, B. Hiner, H. Payami, E. Molho, S.A. Factor, J.G. Nutt, C. Serrano, M. Arroyo, R. Ottman, M.W. Pauciulo, W.C. Nichols, L.N. Clark, and K.S. Marder Cognitive and motor function in long-duration PARKIN-associated Parkinson disease JAMA Neurol. 71 2014 62 67
72. E. Lohmann, S. Thobois, S. Lesage, E. Broussolle, S.T. du Montcel, M.J. Ribeiro, P. Remy, A. Pelissolo, B. Dubois, L. Mallet, P. Pollak, Y. Agid, and A. Brice A multidisciplinary study of patients with early-onset PD with and without parkin mutations Neurology 72 2009 110 116
73. E. Caccappolo, R.N. Alcalay, H. Mejia-Santana, M.X. Tang, B. Rakitin, L. Rosado, E.D. Louis, C.L. Comella, A. Colcher, D. Jennings, M.A. Nance, S. Bressman, W.K. Scott, C.M. Tanner, S.F. Mickel, H.F. Andrews, C. Waters, S. Fahn, L.J. Cote, S. Frucht, B. Ford, M. Rezak, K. Novak, J.H. Friedman, R.F. Pfeiffer, L. Marsh, B. Hiner, A.D. Siderowf, B.M. Ross, M. Verbitsky, S. Kisselev, R. Ottman, L.N. Clark, and K.S. Marder Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD study J. Int. Neuropsychol. Soc. 17 2011 91 100
74. C. Marras, and A. Lang Parkinson's disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84 2013 409 415
75. M.A. Thenganatt, and J. Jankovic Parkinson disease subtypes JAMA Neurol. 71 2014 499 504
76. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
77. P. Ibanez, A.M. Bonnet, B. Debarges, E. Lohmann, F. Tison, P. Pollak, Y. Agid, A. Durr, and A. Brice Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease Lancet 364 2004 1169 1171
78. M. Farrer, J. Kachergus, L. Forno, S. Lincoln, D.S. Wang, M. Hulihan, D. Maraganore, K. Gwinn-Hardy, Z. Wszolek, D. Dickson, and J.W. Langston Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications Ann Neurol. 55 2004 174 179
79. M. Farrer, P. Chan, R. Chen, L. Tan, S. Lincoln, D. Hernandez, L. Forno, K. Gwinn-Hardy, L. Petrucelli, J. Hussey, A. Singleton, C. Tanner, J. Hardy, and J.W. Langston Lewy bodies and Parkinsonism in families with parkin mutations Ann. Neurol. 50 2001 293 300
80. P.P. Pramstaller, M.G. Schlossmacher, T.S. Jacques, F. Scaravilli, C. Eskelson, I. Pepivani, K. Hedrich, S. Adel, M. Gonzales-McNeal, R. Hilker, P.L. Kramer, and C. Klein Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers Ann. Neurol. 58 2005 411 422
81. L. Samaranch, O. Lorenzo-Betancor, J.M. Arbelo, I. Ferrer, E. Lorenzo, J. Irigoyen, M.A. Pastor, C. Marrero, C. Isla, J. Herrera-Henriquez, and P. Pastor PINK1-linked Parkinsonism is associated with Lewy body pathology Brain 133 2010 1128 1142
82. Z.K. Wszolek, R.F. Pfeiffer, Y. Tsuboi, R.J. Uitti, R.D. McComb, A.J. Stoessl, A.J. Strongosky, A. Zimprich, B. Muller-Myhsok, M.J. Farrer, T. Gasser, D.B. Calne, and D.W. Dickson Autosomal dominant Parkinsonism associated with variable synuclein and tau pathology Neurology 62 2004 1619 1622
83. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Muller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology Neuron 44 2004 601 607
84. H. Mori, T. Kondo, M. Yokochi, H. Matsumine, Y. Nakagawa-Hattori, T. Miyake, K. Suda, and Y. Mizuno Pathologic and biochemical studies of juvenile Parkinsonism linked to chromosome 6q Neurology 51 1998 890 892
85. F.C. Joelving, R. Billeskov, J.R. Christensen, M. West, and B. Pakkenberg Hippocampal neuron and glial cell numbers in Parkinson's disease-a stereological study Hippocampus 16 2006 826 833
86. K.J. Klos, J.E. Ahlskog, K.A. Josephs, H. Apaydin, J.E. Parisi, B.F. Boeve, M.W. DeLucia, and D.W. Dickson Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals Neurology 66 2006 1100 1102
87. R.E. Burke, W.T. Dauer, and J.P. Vonsattel A critical evaluation of the Braak staging scheme for Parkinson's disease Ann. Neurol. 64 2008 485 491
88. D.W. Dickson, H. Braak, J.E. Duda, C. Duyckaerts, T. Gasser, G.M. Halliday, J. Hardy, J.B. Leverenz, K. Del Tredici, Z.K. Wszolek, and I. Litvan Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria Lancet Neurol. 8 2009 1150 1157
89. L. Parkkinen, T. Kauppinen, T. Pirttila, J.M. Autere, and I. Alafuzoff Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia Ann. Neurol. 57 2005 82 91
90. A.H. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease J. Neurochem. 54 1990 823 827
91. V.M. Mann, J.M. Cooper, S.E. Daniel, K. Srai, P. Jenner, C.D. Marsden, and A.H.V. Schapira Complex I, iron, and ferritin in Parkinson's disease substantia nigra Ann. Neurol. 36 1994 876 881
92. R.H. Haas, F. Nasirian, K. Nakano, D. Ward, M. Pay, R. Hill, and C.W. Shults Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease Ann. Neurol. 37 1995 714 722
93. W.D. Parker Jr., S.J. Boyson, and J.K. Parks Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann. Neurol. 26 1989 719 723
94. B. Zheng, Z. Liao, J.J. Locascio, K.A. Lesniak, S.S. Roderick, M.L. Watt, A.C. Eklund, Y. Zhang-James, P.D. Kim, M.A. Hauser, E. Grunblatt, L.B. Moran, S.A. Mandel, P. Riederer, R.M. Miller, H.J. Federoff, U. Wullner, S. Papapetropoulos, M.B. Youdim, I. Cantuti-Castelvetri, A.B. Young, J.M. Vance, R.L. Davis, J.C. Hedreen, C.H. Adler, T.G. Beach, M.B. Graeber, F.A. Middleton, J.C. Rochet, and C.R. Scherzer PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease Sci. Transl. Med. 2 2010 52ra73
95. M. Elstner, C.M. Morris, K. Heim, A. Bender, D. Mehta, E. Jaros, T. Klopstock, T. Meitinger, D.M. Turnbull, and H. Prokisch Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death Acta Neuropathol. 122 2011 75 86
96. A. Bender, K.J. Krishnan, C.M. Morris, G.A. Taylor, A.K. Reeve, R.H. Perry, E. Jaros, J.S. Hersheson, J. Betts, T. Klopstock, R.W. Taylor, and D.M. Turnbull High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease Nat. Genet. 38 2006 515 517
97. T. Cali, D. Ottolini, A. Negro, and M. Brini Alpha-synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions J. Biol. Chem. 287 2012 17914 17929
98. V. Choubey, D. Safiulina, A. Vaarmann, M. Cagalinec, P. Wareski, M. Kuum, A. Zharkovsky, and A. Kaasik Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy J. Biol. Chem. 286 2011 10814 10824
99. S.J. Chinta, J.K. Mallajosyula, A. Rane, and J.K. Andersen Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo Neurosci. Lett. 486 2010 235 239
100. A. Siddiqui, S.J. Chinta, J.K. Mallajosyula, S. Rajagopolan, I. Hanson, A. Rane, S. Melov, and J.K. Andersen Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease Free Radical Biol. Med. 53 2012 993 1003
101. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, K.E. Larsen, R. Staal, K. Tieu, Y. Schmitz, C.A. Yuan, M. Rocha, V. Jackson-Lewis, S. Hersch, D. Sulzer, S. Przedborski, R. Burke, and R. Hen Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP Proc. Natl. Acad. Sci. U.S.A. 99 2002 14524 14529
102. P. Klivenyi, D. Siwek, G. Gardian, L. Yang, A. Starkov, C. Cleren, R.J. Ferrante, N.W. Kowall, A. Abeliovich, and M.F. Beal Mice lacking alpha-synuclein are resistant to mitochondrial toxins Neurobiol. Dis. 21 2006 541 548
103. K.L. Norris, R. Hao, L.F. Chen, C.H. Lai, M. Kapur, P.J. Shaughnessy, D. Chou, J. Yan, J.P. Taylor, S. Engelender, A.E. West, K.L. Lim, and T.P. Yao Convergence of Parkin, PINK1, and alpha-synuclein on stress-induced mitochondrial morphological remodeling J. Biol. Chem. 290 2015 13862 13874
104. J. Eschbach, B. von Einem, K. Muller, H. Bayer, A. Scheffold, B.E. Morrison, K.L. Rudolph, D.R. Thal, A. Witting, P. Weydt, M. Otto, M. Fauler, B. Liss, P.J. McLean, A.R. Spada, A.C. Ludolph, J.H. Weishaupt, and K.M. Danzer Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization Ann. Neurol. 77 2015 15 32
105. H. Hall, S. Reyes, N. Landeck, C. Bye, G. Leanza, K. Double, L. Thompson, G. Halliday, and D. Kirik Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease Brain 137 2014 2493 2508
106. D.A. McRitchie, H.R. Cartwright, and G.M. Halliday Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease Exp. Neurol. 144 1997 202 213
107. M.M. Matzuk, and C.B. Saper Preservation of hypothalamic dopaminergic neurons in Parkinson's disease Ann. Neurol. 18 1985 552 555
108. D.C. German, K.F. Manaye, P.K. Sonsalla, and B.A. Brooks Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: sparing of calbindin-D28k-containing cells Ann. N. Y. Acad. Sci. 648 1992 42 62
109. J.G. Greene Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease Antioxid. Redox Signal. 21 2014 649 667
110. D. Sulzer, and D.J. Surmeier Neuronal vulnerability, pathogenesis, and Parkinson's disease Mov. Disord. 28 2013 715 724
111. J. Nunnari, and A. Suomalainen Mitochondria: in sickness and in health Cell 148 2012 1145 1159
112. H.S. Waagepetersen, U. Sonnewald, and A. Schousboe Compartmentation of glutamine, glutamate, and GABA metabolism in neurons and astrocytes: functional implications Neuroscientist 9 2003 398 403
113. M. Gu, J.M. Cooper, J.W. Taanman, and A.H. Schapira Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease Ann. Neurol. 44 1998 177 186
114. R.H. Swerdlow, J.K. Parks, S.W. Miller, J.B. Tuttle, P.A. Trimmer, J.P. Sheehan, J.P. Bennett Jr., R.E. Davis, and W.D. Parker Jr. Origin and functional consequences of the complex I defect in Parkinson's disease Ann. Neurol. 40 1996 663 671
115. D. Pathak, A. Berthet, and K. Nakamura Energy failure: does it contribute to neurodegeneration? Ann. Neurol. 74 2013 506 516
116. D. Pathak, L.Y. Shields, B.A. Mendelsohn, D. Haddad, W. Lin, A.A. Gerencser, H. Kim, M.D. Brand, R.H. Edwards, and K. Nakamura The role of mitochondrially derived ATP in synaptic vesicle recycling J. Biol. Chem. 290 2015 22325 22336
117. L.Y. Shields, H. Kim, L. Zhu, D. Haddad, A. Berthet, D. Pathak, M. Lam, R. Ponnusamy, L.G. Diaz-Ramirez, T.M. Gill, H. Sesaki, L. Mucke, and K. Nakamura Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons Cell Death Dis. 6 2015 e1725
118. M.D. Brand The sites and topology of mitochondrial superoxide production Exp. Gerontol. 45 2010 466 472
119. C. Perier, K. Tieu, C. Guegan, C. Caspersen, V. Jackson-Lewis, V. Carelli, A. Martinuzzi, M. Hirano, S. Przedborski, and M. Vila Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage Proc. Natl. Acad. Sci. U.S.A. 102 2005 19126 19131
120. R.R. Ramsay, and T.P. Singer Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+ Biochem. Biophys. Res. Commun. 189 1992 47 52
121. M.S. Lustgarten, Y.C. Jang, Y. Liu, W. Qi, Y. Qin, P.L. Dahia, Y. Shi, A. Bhattacharya, F.L. Muller, T. Shimizu, T. Shirasawa, A. Richardson, and H. Van Remmen MnSOD deficiency results in elevated oxidative stress and decreased mitochondrial function but does not lead to muscle atrophy during aging Aging Cell 10 2011 493 505
122. A.L. Orr, D. Ashok, M.R. Sarantos, T. Shi, R.E. Hughes, and M.D. Brand Inhibitors of ROS production by the ubiquinone-binding site of mitochondrial complex I identified by chemical screening Free Radical Biol Med. 65 2013 1047 1059
123. J. Sian, D.T. Dexter, A.J. Lees, S. Daniel, Y. Agid, F. Javoy-Agid, P. Jenner, and C.D. Marsden Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann. Neurol. 36 1994 348 355
124. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C.D. Marsden Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J. Neurochem. 52 1989 381 389
125. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E.R. Stadtman, and Y. Mizuno Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 93 1996 2696 2701
126. Z.I. Alam, S.E. Daniel, A.J. Lees, D.C. Marsden, P. Jenner, and B. Halliwell A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease J. Neurochem. 69 1997 1326 1329
127. Z.I. Alam, A. Jenner, S.E. Daniel, A.J. Lees, N. Cairns, C.D. Marsden, P. Jenner, and B. Halliwell Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hudroxyguanine levels in substantia nigra J. Neurochem. 69 1997 1196 1203
128. G.S. Gaki, and A.G. Papavassiliou Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease Neuromol. Med. 16 2014 217 230
129. C. Zhou, Y. Huang, and S. Przedborski Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance Ann. N. Y. Acad. Sci. 1147 2008 93 104
130. T.J. Montine, M.J. Picklo, V. Amarnath, W.O. Whetsell Jr., and D.G. Graham Neurotoxicity of endogenous cysteinylcatechols Exp. Neurol. 148 1997 26 33
131. S.B. Berman, and T.G. Hastings Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J. Neurochem. 73 1999 1127 1137
132. W.M. Caudle, J.R. Richardson, M.Z. Wang, T.N. Taylor, T.S. Guillot, A.L. McCormack, R.E. Colebrooke, D.A. Di Monte, P.C. Emson, and G.W. Miller Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J. Neurosci. 27 2007 8138 8148
133. E.V. Mosharov, K.E. Larsen, E. Kanter, K.A. Phillips, K. Wilson, Y. Schmitz, D.E. Krantz, K. Kobayashi, R.H. Edwards, and D. Sulzer Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 62 2009 218 229
134. K. Nakamura, V.P. Bindokas, D. Kowlessur, M. Elas, S. Milstien, J.D. Marks, H.J. Halpern, and U.J. Kang Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons J. Biol. Chem. 276 2001 34402 34407
135. K. Nakamura, D.A. Wright, T. Wiatr, D. Kowlessur, S. Milstien, X.G. Lei, and U.J. Kang Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin J. Neurochem. 74 2000 2305 2315
136. D.I. Dryanovski, J.N. Guzman, Z. Xie, D.J. Galteri, L.A. Volpicelli-Daley, V.M. Lee, R.J. Miller, P.T. Schumacker, and D.J. Surmeier Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons J. Neurosci. 33 2013 10154 10164
137. E.C. Hirsch Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease Ann. Neurol. 32 1992 S88 S93
138. A.M. Brennan, S.W. Suh, S.J. Won, P. Narasimhan, T.M. Kauppinen, H. Lee, Y. Edling, P.H. Chan, and R.A. Swanson NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation Nat. Neurosci. 12 2009 857 863
139. S. Kovac, A.M. Domijan, M.C. Walker, and A.Y. Abramov Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation Cell Death Dis. 5 2014 e1442
140. Y. Kirichok, G. Krapivinsky, and D.E. Clapham The mitochondrial calcium uniporter is a highly selective ion channel Nature 427 2004 360 364
141. J.M. Baughman, F. Perocchi, H.S. Girgis, M. Plovanich, C.A. Belcher-Timme, Y. Sancak, X.R. Bao, L. Strittmatter, O. Goldberger, R.L. Bogorad, V. Koteliansky, and V.K. Mootha Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter Nature 476 2011 341 345
142. J. Santo-Domingo, and N. Demaurex Calcium uptake mechanisms of mitochondria Biochim. Biophys. Acta 1797 2010 907 912
143. H.F. Deluca, and G.W. Engstrom Calcium uptake by rat kidney mitochondria Proc. Natl. Acad. Sci. U.S.A. 47 1961 1744 1750
144. D.G. Nicholls The regulation of extramitochondrial free calcium ion concentration by rat liver mitochondria Biochem. J. 176 1978 463 474
145. R. Moreno-Sanchez Regulation of oxidative phosphorylation in mitochondria by external free Ca2+ concentrations J. Biol. Chem. 260 1985 4028 4034
146. I. Llorente-Folch, C.B. Rueda, B. Pardo, G. Szabadkai, M.R. Duchen, and J. Satrustegui The regulation of neuronal mitochondrial metabolism by calcium J. Physiol. 593 2015 3447 3462
147. B. Glancy, and R.S. Balaban Role of mitochondrial Ca2+ in the regulation of cellular energetics Biochemistry 51 2012 2959 2973
148. P.R. Territo, V.K. Mootha, S.A. French, and R.S. Balaban Ca(2+) activation of heart mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase Am. J. Physiol. Cell Physiol. 278 2000 C423 C435
149. R.M. Denton Regulation of mitochondrial dehydrogenases by calcium ions Biochim. Biophys. Acta 1787 2009 1309 1316
150. D.J. Surmeier, and P.T. Schumacker Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease J. Biol. Chem. 288 2013 10736 10741
151. I. Llorente-Folch, C.B. Rueda, I. Amigo, A. del Arco, T. Saheki, B. Pardo, and J. Satrustegui Calcium-regulation of mitochondrial respiration maintains ATP homeostasis and requires ARALAR/AGC1-malate aspartate shuttle in intact cortical neurons J. Neurosci. 33 2013 13957-71, 13971a
152. C.L. Liang, C.M. Sinton, and D.C. German Midbrain dopaminergic neurons in the mouse: co-localization with calbindin-D28K and calretinin Neuroscience 75 1996 523 533
153. L. Scorrano, S.A. Oakes, J.T. Opferman, E.H. Cheng, M.D. Sorcinelli, T. Pozzan, and S.J. Korsmeyer BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis Science 300 2003 135 139
154. D.M. Arduino, A.R. Esteves, S.M. Cardoso, and C.R. Oliveira Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson's disease Neurochem. Int. 55 2009 341 348
155. G. Santulli, W. Xie, S.R. Reiken, and A.R. Marks Mitochondrial calcium overload is a key determinant in heart failure Proc. Natl. Acad. Sci. U.S.A. 2015
156. 2+ and apoptosis Cell Calcium 52 2012 36 43
157. S. Gandhi, A. Wood-Kaczmar, Z. Yao, H. Plun-Favreau, E. Deas, K. Klupsch, J. Downward, D.S. Latchman, S.J. Tabrizi, N.W. Wood, M.R. Duchen, and A.Y. Abramov PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death Mol. Cell 33 2009 627 638
158. R. Rizzuto, P. Pinton, W. Carrington, F.S. Fay, K.E. Fogarty, L.M. Lifshitz, R.A. Tuft, and T. Pozzan Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses Science 280 1998 1763 1766
159. C. Lopez-Crisosto, R. Bravo-Sagua, M. Rodriguez-Pena, C. Mera, P.F. Castro, A.F. Quest, B.A. Rothermel, M. Cifuentes, and S. Lavandero ER-to-mitochondria miscommunication and metabolic diseases Biochim. Biophys. Acta 1852 2015 2096 2105
160. C. Cardenas, R.A. Miller, I. Smith, T. Bui, J. Molgo, M. Muller, H. Vais, K.H. Cheung, J. Yang, I. Parker, C.B. Thompson, M.J. Birnbaum, K.R. Hallows, and J.K. Foskett Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria Cell 142 2010 270 283
161. C. Guardia-Laguarta, E. Area-Gomez, C. Rub, Y. Liu, J. Magrane, D. Becker, W. Voos, E.A. Schon, and S. Przedborski Alpha-Synuclein is localized to mitochondria-associated ER membranes J. Neurosci. 34 2014 249 259
162. D. Ottolini, T. Cali, A. Negro, and M. Brini The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering Hum. Mol. Genet. 22 2013 2152 2168
163. T. Cali, D. Ottolini, A. Negro, and M. Brini Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics Biochim. Biophys. Acta 1832 2013 495 508
164. R. Brauer, K. Bhaskaran, N. Chaturvedi, D.T. Dexter, L. Smeeth, and I. Douglas Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study PLoS Med. 12 2015 e1001854
165. A. Shaltouki, R. Sivapatham, Y. Pei, A.A. Gerencser, O. Momcilovic, M.S. Rao, and X. Zeng Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines Stem Cell Rep. 4 2015 847 859
166. C.A. Gautier, T. Kitada, and J. Shen Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress Proc. Natl. Acad. Sci. U.S.A. 105 2008 11364 11369
167. S. Gispert, F. Ricciardi, A. Kurz, M. Azizov, H.H. Hoepken, D. Becker, W. Voos, K. Leuner, W.E. Muller, A.P. Kudin, W.S. Kunz, A. Zimmermann, J. Roeper, D. Wenzel, M. Jendrach, M. Garcia-Arencibia, J. Fernandez-Ruiz, L. Huber, H. Rohrer, M. Barrera, A.S. Reichert, U. Rub, A. Chen, R.L. Nussbaum, and G. Auburger Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration PLoS One 4 2009 e5777
168. A.M. Pickrell, C.H. Huang, S.R. Kennedy, A. Ordureau, D.P. Sideris, J.G. Hoekstra, J.W. Harper, and R.J. Youle Endogenous Parkin preserves dopaminergic substantia nigral neurons following mitochondrial DNA mutagenic stress Neuron 87 2015 371 381
169. C.L. Liang, T.T. Wang, K. Luby-Phelps, and D.C. German Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease Exp. Neurol. 203 2007 370 380
170. D.S. Beattie The turnover of the protein components of the inner and outer membrane fractions of rat liver mitochondria Biochem. Biophys. Res. Commun. 35 1969 721 727
171. E.S. Vincow, G. Merrihew, R.E. Thomas, N.J. Shulman, R.P. Beyer, M.J. MacCoss, and L.J. Pallanck The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo Proc. Natl. Acad. Sci. U.S.A. 110 2013 6400 6405
172. A. Sugiura, G.L. McLelland, E.A. Fon, and H.M. McBride A new pathway for mitochondrial quality control: mitochondrial-derived vesicles EMBO J. 33 2014 2142 2156
173. V.K. Godena, N. Brookes-Hocking, A. Moller, G. Shaw, M. Oswald, R.M. Sancho, C.C. Miller, A.J. Whitworth, and K.J. De Vos Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations Nat Commun. 5 2014 5245
174. L. Li, S. Nadanaciva, Z. Berger, W. Shen, K. Paumier, J. Schwartz, K. Mou, P. Loos, A.J. Milici, J. Dunlop, and W.D. Hirst Human A53T alpha-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons PLoS One 8 2013 e85815
175. P.M. Rappold, M. Cui, J.C. Grima, R.Z. Fan, K.L. de Mesy-Bentley, L. Chen, X. Zhuang, W.J. Bowers, and K. Tieu Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo Nat. Commun. 5 2014 5244
176. T. Sun, H. Qiao, P.Y. Pan, Y. Chen, and Z.H. Sheng Motile axonal mitochondria contribute to the variability of presynaptic strength Cell Rep. 4 2013 413 419
177. S.A. Detmer, and D.C. Chan Functions and dysfunctions of mitochondrial dynamics Nat. Rev. Mol. Cell Biol. 8 2007 870 879
178. A. Tanaka, M.M. Cleland, S. Xu, D.P. Narendra, D.F. Suen, M. Karbowski, and R.J. Youle Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin J. Cell Biol. 191 2010 1367 1380
179. A. Berthet, E.B. Margolis, J. Zhang, I. Hsieh, T.S. Hnasko, J. Ahmad, R.H. Edwards, H. Sesaki, E.J. Huang, and K. Nakamura Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons J. Neurosci. 34 2014 14304 14317
180. A.H. Pham, S. Meng, Q.N. Chu, and D.C. Chan Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit Hum. Mol. Genet. 21 2012 4817 4826
181. V. Carelli, O. Musumeci, L. Caporali, C. Zanna, C. La Morgia, V. Del Dotto, A.M. Porcelli, M. Rugolo, M.L. Valentino, L. Iommarini, A. Maresca, P. Barboni, M. Carbonelli, C. Trombetta, E.M. Valente, S. Patergnani, C. Giorgi, P. Pinton, G. Rizzo, C. Tonon, R. Lodi, P. Avoni, R. Liguori, A. Baruzzi, A. Toscano, and M. Zeviani Syndromic Parkinsonism and dementia associated with OPA1 missense mutations Ann. Neurol. 78 2015 21 38
182. E. Ziviani, R.N. Tao, and A.J. Whitworth Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin Proc. Natl. Acad. Sci. U.S.A. 107 2010 5018 5023
183. B. Picconi, G. Piccoli, and P. Calabresi Synaptic dysfunction in Parkinson's disease Adv. Exp. Med. Biol. 970 2012 553 572
184. H.J. Cho, J. Yu, C. Xie, P. Rudrabhatla, X. Chen, J. Wu, L. Parisiadou, G. Liu, L. Sun, B. Ma, J. Ding, Z. Liu, and H. Cai Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export EMBO J. 33 2014 2314 2331
185. A.M. Cuervo, L. Stefanis, R. Fredenburg, P.T. Lansbury, and D. Sulzer Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 2004 1292 1295
186. D. Attwell, and S.B. Laughlin An energy budget for signaling in the grey matter of the brain J. Cereb. Blood Flow Metab. 21 2001 1133 1145
187. C.S. Chan, J.N. Guzman, E. Ilijic, J.N. Mercer, C. Rick, T. Tkatch, G.E. Meredith, and D.J. Surmeier 'Rejuvenation' protects neurons in mouse models of Parkinson's disease Nature 447 2007 1081 1086
188. B. Liss, O. Haeckel, J. Wildmann, T. Miki, S. Seino, and J. Roeper K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons Nat. Neurosci. 8 2005 1742 1751
189. J. Schiemann, F. Schlaudraff, V. Klose, M. Bingmer, S. Seino, P.J. Magill, K.A. Zaghloul, G. Schneider, B. Liss, and J. Roeper K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration Nat. Neurosci. 15 2012 1272 1280
190. M.J. Zigmond, A.L. Acheson, M.K. Stachowiak, and E.M. Stricker Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism Arch. Neurol. 41 1984 856 861
191. M.K. Stachowiak, R.W. Keller Jr., E.M. Stricker, and M.J. Zigmond Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage J. Neurosci. 7 1987 1648 1654
192. T.E. Robinson, and I.Q. Whishaw Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats Brain Res. 450 1988 209 224
193. J.R. Hollerman, and A.A. Grace The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons Brain Res. 533 1990 203 212
194. M.W. Bishop, S. Chakraborty, G.A. Matthews, A. Dougalis, N.W. Wood, R. Festenstein, and M.A. Ungless Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice J. Neurophysiol. 104 2010 3009 3020
195. M. Subramaniam, D. Althof, S. Gispert, J. Schwenk, G. Auburger, A. Kulik, B. Fakler, and J. Roeper Mutant alpha-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels J. Neurosci. 34 2014 13586 13599
196. R.C. Foehring, X.F. Zhang, J.C. Lee, and J.C. Callaway Endogenous calcium buffering capacity of substantia nigral dopamine neurons J. Neurophysiol. 102 2009 2326 2333
197. W. Matsuda, T. Furuta, K.C. Nakamura, H. Hioki, F. Fujiyama, R. Arai, and T. Kaneko Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum J. Neurosci. 29 2009 444 453
198. J.P. Bolam, and E.K. Pissadaki Living on the edge with too many mouths to feed: why dopamine neurons die Mov. Disord. 27 2012 1478 1483
199. J.J. Harris, and D. Attwell The energetics of CNS white matter J. Neurosci. 32 2012 356 371
200. H. Braak, and K. Del Tredici Poor and protracted myelination as a contributory factor to neurodegenerative disorders Neurobiol. Aging 25 2004 19 23
201. S. Orimo, T. Uchihara, T. Kanazawa, Y. Itoh, K. Wakabayashi, A. Kakita, and H. Takahashi Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease Neuropathol. Appl. Neurobiol. 37 2011 791 802
202. C. Hildebrand, S. Remahl, H. Persson, and C. Bjartmar Myelinated nerve fibres in the CNS Prog. Neurobiol. 40 1993 319 384
203. U. Funfschilling, L.M. Supplie, D. Mahad, S. Boretius, A.S. Saab, J. Edgar, B.G. Brinkmann, C.M. Kassmann, I.D. Tzvetanova, W. Mobius, F. Diaz, D. Meijer, U. Suter, B. Hamprecht, M.W. Sereda, C.T. Moraes, J. Frahm, S. Goebbels, and K.A. Nave Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity Nature 485 2012 517 521
204. S.W. Scheff, D.A. Price, F.A. Schmitt, S.T. DeKosky, and E.J. Mufson Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment Neurology 68 2007 1501 1508
205. H. Li, S.H. Li, Z.X. Yu, P. Shelbourne, and X.J. Li Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice J. Neurosci. 21 2001 8473 8481
206. H.C. Cheng, C.M. Ulane, and R.E. Burke Clinical progression in Parkinson disease and the neurobiology of axons Ann. Neurol. 67 2010 715 725
207. Y. Chu, G.A. Morfini, L.B. Langhamer, Y. He, S.T. Brady, and J.H. Kordower Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease Brain 135 2012 2058 2073
208. A. Berthet, E.B. Margolis, J. Zhang, I. Hsieh, J. Zhang, T.S. Hnasko, J. Ahmad, R.H. Edwards, H. Sesaki, E.J. Huang, and K. Nakamura Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons J. Neurosci. 34 2014 14304 14317
209. T.J. Collier, N.M. Kanaan, and J.H. Kordower Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates Nat. Rev. Neurosci. 12 2011 359 366
210. C. Lopez-Otin, M.A. Blasco, L. Partridge, M. Serrano, and G. Kroemer The hallmarks of aging Cell 153 2013 1194 1217
211. Y.C. Jang, and H. Van Remmen The mitochondrial theory of aging: insight from transgenic and knockout mouse models Exp. Gerontol. 44 2009 256 260
212. A. Bratic, and N.G. Larsson The role of mitochondria in aging J. Clin. Invest. 123 2013 951 957
213. J. Miquel, A.C. Economos, J. Fleming, and J.E. Johnson Jr. Mitochondrial role in cell aging Exp. Gerontol. 15 1980 575 591
214. M.H. Pontes, A. Sevostyanova, and E.A. Groisman When too much ATP Is bad for protein synthesis J. Mol. Biol. 427 2015 2586 2594
215. J.M. Xavier, C.M. Rodrigues, and S. Sola Mitochondria: major regulators of neural development Neuroscientist 2015
216. M. Vos, E. Lauwers, and P. Verstreken Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease Front. Synaptic Neurosci. 2 2010 139
217. S. Cunnane, S. Nugent, M. Roy, A. Courchesne-Loyer, E. Croteau, S. Tremblay, A. Castellano, F. Pifferi, C. Bocti, N. Paquet, H. Begdouri, M.h. Bentourkia, E. Turcotte, M. Allard, P. Barberger-Gateau, T. Fulop, and S.I. Rapoport Brain fuel metabolism, aging, and Alzheimer's disease Nutrition 27 2011 3 20
218. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators K. Kieburtz, B.C. Tilley, J.J. Elm, D. Babcock, R. Hauser, G.W. Ross, A.H. Augustine, E.U. Augustine, M.J. Aminoff, I.G. Bodis-Wollner, J. Boyd, F. Cambi, K. Chou, C.W. Christine, M. Cines, N. Dahodwala, L. Derwent, R.B. Dewey Jr., K. Hawthorne, D.J. Houghton, C. Kamp, M. Leehey, M.F. Lew, G.S. Liang, S.T. Luo, Z. Mari, J.C. Morgan, S. Parashos, A. Perez, H. Petrovitch, S. Rajan, S. Reichwein, J.T. Roth, J.S. Schneider, K.M. Shannon, D.K. Simon, T. Simuni, C. Singer, L. Sudarsky, C.M. Tanner, C.C. Umeh, K. Williams, and A.M. Wills Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial JAMA 313 2015 584 593
219. M.F. Beal, D. Oakes, I. Shoulson, C. Henchcliffe, W.R. Galpern, R. Haas, J.L. Juncos, J.G. Nutt, T.S. Voss, B. Ravina, C.M. Shults, K. Helles, V. Snively, M.F. Lew, B. Griebner, A. Watts, S. Gao, E. Pourcher, L. Bond, K. Kompoliti, P. Agarwal, C. Sia, M. Jog, L. Cole, M. Sultana, R. Kurlan, I. Richard, C. Deeley, C.H. Waters, A. Figueroa, A. Arkun, M. Brodsky, W.G. Ondo, C.B. Hunter, J. Jimenez-Shahed, A. Palao, J.M. Miyasaki, J. So, J. Tetrud, L. Reys, K. Smith, C. Singer, A. Blenke, D.S. Russell, C. Cotto, J.H. Friedman, M. Lannon, L. Zhang, E. Drasby, R. Kumar, T. Subramanian, D.S. Ford, D.A. Grimes, D. Cote, J. Conway, A.D. Siderowf, M.L. Evatt, B. Sommerfeld, A.N. Lieberman, M.S. Okun, R.L. Rodriguez, S. Merritt, C.L. Swartz, W.R. Martin, P. King, N. Stover, S. Guthrie, R.L. Watts, A. Ahmed, H.H. Fernandez, A. Winters, Z. Mari, T.M. Dawson, B. Dunlop, A.S. Feigin, B. Shannon, M.J. Nirenberg, M. Ogg, S.A. Ellias, C.A. Thomas, K. Frei, I. Bodis-Wollner, S. Glazman, T. Mayer, R.A. Hauser, R. Pahwa, A. Langhammer, R. Ranawaya, L. Derwent, K.D. Sethi, B. Farrow, R. Prakash, I. Litvan, A. Robinson, A. Sahay, M. Gartner, V.K. Hinson, S. Markind, M. Pelikan, J.S. Perlmutter, and et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit JAMA Neurol. 71 2014 543 552
220. S. Mercimek-Mahmutoglu, G. Sinclair, S.J. van Dooren, W. Kanhai, P. Ashcraft, O.J. Michel, J. Nelson, O.T. Betsalel, L. Sweetman, C. Jakobs, and G.S. Salomons Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease Mol. Genet. Metab. 107 2012 433 437
221. O. Braissant GAMT deficiency: 20 years of a treatable inborn error of metabolism Mol. Genet. Metab. 111 2014 1 3
222. A. Rotig, E.L. Appelkvist, V. Geromel, D. Chretien, N. Kadhom, P. Edery, M. Lebideau, G. Dallner, A. Munnich, L. Ernster, and P. Rustin Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency Lancet 356 2000 391 395
223. A.J. Duncan, M. Bitner-Glindzicz, B. Meunier, H. Costello, I.P. Hargreaves, L.C. Lopez, M. Hirano, C.M. Quinzii, M.I. Sadowski, J. Hardy, A. Singleton, P.T. Clayton, and S. Rahman A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease Am. J. Hum. Genet. 84 2009 558 566
224. A. Ramm-Pettersen, K.E. Stabell, K.O. Nakken, and K.K. Selmer Does ketogenic diet improve cognitive function in patients with GLUT1-DS? A 6- to 17-month follow-up study Epilepsy Behav. 39 2014 111 115
225. J. Klepper GLUT1 deficiency syndrome and ketogenic diet therapies: missing rare but treatable diseases? Dev. Med. Child Neurol. 2015
226. S. Song, S. Jang, J. Park, S. Bang, S. Choi, K.Y. Kwon, X. Zhuang, E. Kim, and J. Chung Characterization of PINK1 (PTEN-induced putative kinase 1) mutations associated with Parkinson disease in mammalian cells and Drosophila J. Biol. Chem. 288 2013 5660 5672
227. N.T. Hertz, A. Berthet, M.L. Sos, K.S. Thorn, A.L. Burlingame, K. Nakamura, and K.M. Shokat A neo-substrate that amplifies catalytic activity of Parkinson's-disease-related kinase PINK1 Cell 154 2013 737 747
228. M.S. Vandiver, B.D. Paul, R. Xu, S. Karuppagounder, F. Rao, A.M. Snowman, H.S. Ko, Y.I. Lee, V.L. Dawson, T.M. Dawson, N. Sen, and S.H. Snyder Sulfhydration mediates neuroprotective actions of parkin Nat. Commun. 4 2013 1626
229. G. Parkinson Study Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD) Mov. Disord. 28 2013 1823 1831